Inside Psychiatry’s Battle to Define Mental Illness

The authoritative expert who chaired the DSM-IV revision has become a formidable critic whose publicly expressed views about psychiatry’s diagnostic assessments and prescribed treatments–mostly chemical interventions–validate the criticism expressed by the Alliance for Human Research Protection for more than a dozen years. Continue reading →

Parity Likely to Increase Wholesale Sedation of Children

"For her last month of life, Kifuji overall prescribed 835 pills to Rebecca….If what Dr. Kifuji did in this case is the acceptable standard of care for children in Massachusetts, then there is something very wrong in this state."  

Continue reading →

Obama Threatens Veto / CIA Experiment Spiked French Bread with LSD

The Obama Administration opposes a proposed independent probe by the Inspector General of the anthrax-laced letter attacks, arguing that it would "undermine public confidence” in a Federal Bureau of Investigation probe of the attacks “and unfairly cast doubt on its conclusions.” 
Continue reading →

Is the Schizophrenia Mortality Study in The Lancet CREDIBLE?

Unless the overall treatment and services provided to schizophrenia patients in Finland is unique and especially protective—which the authors do not suggest—their claimed findings of lowered mortality rates for antipsychotic drug users are belied by a consistent body of evidence. 

Continue reading →

Is FDA Bipolar or Complicit in Legitimizing Illegal Marketing?

The FDA’s expanded marketing approval process for antipsychotics, highly toxic drugs, is unaffected by evidence uncovered by the US Justice Department showing that the studies submitted by drug manufacturers were often flawed, if not fraudulent. Continue reading →

Marketing Trumps Safety: the case of Antipsychotics

"The story’s pretty clear, and pretty embarrassing for the profession of psychiatry, which has allowed itself to be led by marketing," says Dr. Robert Rosenheck, Yale. Continue reading →